Drug intelligence / Profile preview

SL0349

Development stage: Unknown
Modality: Cell Therapies, Gene Silencing → Gene Therapies, Antibody-Based Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

SL0349 is an experimental bispecific nanobody-based chimeric antigen receptor (CAR) construct used in preclinical studies of CAR-T cell therapy. It was identified as an optimized bispecific CAR candidate with significantly enhanced cytotoxic activity in vitro compared with earlier constructs in the same series, suggesting improved target engagement and T cell activation, although specific antigen targets and clinical indications have not yet been disclosed in publicly available sources.

Beyond the preview

Go deeper on SL0349.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL0349.

Explore the full profile